Clinical Trials Logo

Filter by:
NCT ID: NCT01004224 Completed - Clinical trials for Advanced Solid Tumors With FGFR1 Amplication

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Start date: December 11, 2009
Phase: Phase 1
Study type: Interventional

The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.

NCT ID: NCT01004211 Completed - Clinical trials for Non Muscle Invasive Bladder Cancer

Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging

Start date: August 2009
Phase: N/A
Study type: Interventional

To date, fluorescence and narrow band imaging cystoscopy have been tested in many prospective within patient trials but only as an "add on" procedure. This results in a bias that does not allow to determine the real impact of such innovative technologies on bladder cancer management. Hereby we propose the first prospective randomized trial which compares narrow band imaging trans urethral resection as a stand alone procedure versus white light transurethral resection. The primary end point is to assess the recurrence rate of bladder cancer lesions with each treatment modality. The study is designed to disclose an inferior recurrence rate (estimated 10%) in the group treated by narrow band imaging transurethral resection respect to the control group, treated by standard transurethral resection.

NCT ID: NCT01004068 Completed - Clinical trials for Polycystic Ovary Syndrome

Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS)

Start date: February 2008
Phase: Phase 4
Study type: Interventional

Clomiphene citrate (CC) is the first-line therapy for infertile women with polycystic ovary syndrome (PCOS). Unfortunately, at least 20% of PCOS results are not responsive to CC. Structured exercise training (SET) and diet has been successfully employed to restore ovarian function and to improve reproductive outcomes in obese and overweight women with PCOS. The current study was aimed to test the hypothesis that a short-term SET program plus diet intervention can improve the ovarian response to CC in CC-resistant PCOS patients.

NCT ID: NCT01004029 Completed - Preterm Birth Clinical Trials

Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery

PROLONG
Start date: October 2009
Phase: Phase 3
Study type: Interventional

As part of the continuing effort to study the benefit and risks of 17P and preterm delivery, this study is designed as a multi-center, randomized, double-blind, vehicle-controlled clinical trial of 17P for the prevention of preterm birth prior to 35 weeks, 0 days of gestation in women with a singleton pregnancy, aged 18 years or older, with a previous singleton spontaneous preterm delivery. The study also includes a population pharmacokinetic (PK) substudy to assess the hydroxyprogesterone caproate (HPC) exposure-response relationship and the effect of body mass index (BMI) on the PK of 17P.

NCT ID: NCT01003990 Completed - HIV Clinical Trials

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

Start date: October 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide atazanavir or tenofovir-emtricitabine to HIV-infected subjects who have completed atazanavir or tenofovir-emtricitabine therapy on a previous BMS sponsored clinical trial

NCT ID: NCT01003457 Completed - Clinical trials for Detrusor Overactivity

Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity

Start date: January 2005
Phase: N/A
Study type: Observational

In the last decade, several authors proposed ultrasound measurement of Bladder wall thickness (BWT) for the screening of the voiding dysfunction and of the detrusor overactivity (DO). The aims of the investigator prospective study were: - to compare the ultrasonographic measurement of BWT in women with DO vs women with other urodynamic diagnosis in a very large population. - to verify whether the BWT in women with DO can be different in the clinically or urodinamically different forms of DO.

NCT ID: NCT01003015 Completed - Clinical trials for Carcinoma, Hepatocellular

Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma

Start date: September 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether BAY73-4506 treatment is safe and can shrink or delay the growth of tumors in patients with unresectable liver cancer.

NCT ID: NCT01001494 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Start date: October 2009
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to assess the long term bronchodilator efficacy, safety and tolerability of inhaled aclidinium bromide at two dose levels compared to placebo in COPD patients and the benefits of the product in disease-related health status, COPD symptoms and COPD exacerbations.

NCT ID: NCT01001377 Completed - Clinical trials for Metastatic Colorectal Cancer

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Start date: February 2, 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.

NCT ID: NCT01000727 Completed - Clinical trials for Acute Coronary Syndrome

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

SOLID-TIMI 52
Start date: December 2009
Phase: Phase 3
Study type: Interventional

This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).